The utilities used for analysis of cost-effectiveness with plausible ranges for a sensitivity analysis
| Health states . | QALY . | |
|---|---|---|
| Baseline . | Range . | |
| MMR, MR4.5, MR4.0 | 0.9 | 0.765-0.99 |
| CCyR | 0.89 | 0.78-0.94 |
| Untreated or CP not responding to treatment | 0.75 | 0.57-0.85 |
| Intolerance to TKI | 0.58 | 0.38-0.76 |
| AP/BC | 0.22 | 0.07-0.34 |
| Allogeneic SCT, within 1 y | 0.6 | 0.51-0.69 |
| Allogeneic SCT, after 1 y | 0.85 | 0.723-0.978 |
| Death | 0 | 0 |
| TFR | 1 | 0.85-1 |
| Health states . | QALY . | |
|---|---|---|
| Baseline . | Range . | |
| MMR, MR4.5, MR4.0 | 0.9 | 0.765-0.99 |
| CCyR | 0.89 | 0.78-0.94 |
| Untreated or CP not responding to treatment | 0.75 | 0.57-0.85 |
| Intolerance to TKI | 0.58 | 0.38-0.76 |
| AP/BC | 0.22 | 0.07-0.34 |
| Allogeneic SCT, within 1 y | 0.6 | 0.51-0.69 |
| Allogeneic SCT, after 1 y | 0.85 | 0.723-0.978 |
| Death | 0 | 0 |
| TFR | 1 | 0.85-1 |
QALYs other than TFR were extracted from the original model.8 β distributions were used for utilities in probabilistic sensitivity analysis.